SCHEMBL1344909

SCHEMBL1344909

CC(=O)Nc1cc(Cc2sccc2-c2nnc(Nc3ccccc3)s2)ccn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIP5K1C O60331 1/20 0.41
PIK3CA P42336 1/20 0.41
NR3C2 P08235 5/20 0.40
BUB1 O43683 8/20 0.40
MAPK14 Q16539 1/20 0.39
AURKA O14965 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
TSHR P16473 1/20 0.38
PIK3C3 Q8NEB9 1/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
HPGD P15428 1/20 0.37
AHR P35869 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1346590 0.91 LMNA (0.42) MAPK14NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL1344657 0.91 SMN1; SMN2 (0.38) MAPK14PIK3C3NPC1RAB9ASMN1; SMN2
SCHEMBL1346766 0.89 NR3C2 (0.46) NR3C2MAPK14AURKAPIK3C3
SCHEMBL1346459 0.89 NR3C2 (0.45) NR3C2MAPK14
SCHEMBL1346935 0.86 BRAF (0.44) GSK3B
SCHEMBL1344656 0.83 GSK3B (0.44) PIP5K1CPIK3CANR3C2AURKAGSK3A
SCHEMBL1346639 0.82 PIK3CD (0.42) PIK3CATSHRNPC1RAB9ASMN1; SMN2
SCHEMBL1344907 0.80 KMT2A (0.52) PIP5K1CPIK3CABUB1MAPK14AURKA
SCHEMBL1346716 0.79 GSK3B (0.44) PIP5K1CPIK3CABUB1MAPK14AURKA
SCHEMBL1344886 0.79 NPC1 (0.46) PIK3CATSHRNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063034-B2 Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-11-22 US claimed
US-20100016354-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY SANTEN PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US claimed
EP-2128156-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITING ACTIVITY Santen Pharmaceutical Co., Ltd (JP) 2009-12-02 EP claimed
US-8063034-B2 Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-11-22 US disclosed
US-20100016354-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY SANTEN PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128156-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITING ACTIVITY Santen Pharmaceutical Co., Ltd (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016354-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY FLT4, VEGFA, FLT1 PIP5K1C 3563/4885PIK3CA 2790/4885NR3C2 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.